A5069764172- COVID-19 Clinical Research Studies
- Travel-related health issues
- Hepatitis Viruses Studies and Epidemiology
- SARS-CoV-2 and COVID-19 Research
- Complement system in diseases
- Autoimmune Neurological Disorders and Treatments
- Peripheral Neuropathies and Disorders
- Actinomycetales infections and treatment
- Disaster Response and Management
- Salmonella and Campylobacter epidemiology
- Vitamin C and Antioxidants Research
- Drug-Induced Hepatotoxicity and Protection
- Oral microbiology and periodontitis research
- Bacillus and Francisella bacterial research
- Vector-borne infectious diseases
- Probiotics and Fermented Foods
- Long-Term Effects of COVID-19
- Electrolyte and hormonal disorders
- Neurological and metabolic disorders
- Pharmacology and Obesity Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Tuberculosis Research and Epidemiology
- Infectious Encephalopathies and Encephalitis
- Viral gastroenteritis research and epidemiology
- Veterinary medicine and infectious diseases
Hôpital Laveran
2015-2025
Aix-Marseille Université
2017-2019
Institut de Recherche pour le Développement
2018
Service de Santé des Armées
2018
Hôpital de la Timone
2016
Coronavirus disease 2019 (COVID-19) is a caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in pandemic1. The C5a complement factor its receptor C5aR1 (also known as CD88) have key role the initiation maintenance of several inflammatory responses recruiting activating neutrophils monocytes1. Here we provide longitudinal analysis immune responses, including phenotypic analyses cells assessments soluble factors that are present blood...
OBJECTIVES: Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19. DESIGN: FOR COVID Elimination (FORCE) was a double-blind, placebo-controlled study. SETTING: Twelve clinical sites France (ICU general hospitals). PATIENTS: Patients receiving greater than or equal to 5 L oxygen/min maintain Sp o 2 93% (World Health Organization scale ≥ 5). received conventional oxygen therapy high-flow...
Strain EL1T was isolated from a sinus sample of an 85-year-old man with chronic refractory sinusitis complicating ethmoidal adenocarcinoma. We studied its phenotypic and genomic characteristics. This is Gram stain-positive, anaerobic microaerophilic coccus. Cells are catalase negative, nonmotile non-spore forming. The major fatty acids saturated hexadecanoic acid (34%), unsaturated 9-octadecenoic (32%) 9.12-octadecadienoic (21%). 1.86 Mb long genome exhibits 29.9% G+C content contains 1750...
<title>Abstract</title> Coronavirus disease 2019 (COVID-19) is a new pandemic acute respiratory caused by infection with severe syndrome coronavirus 2 (SARS-CoV-2)<sup>11-3</sup>. We provide here longitudinal analysis of immune responses, including cell phenotyping and assessments the soluble factors present in blood broncho-alveolar lavage fluid (BALF) patients at various stages COVID-19 severity: paucisymptomatic, pneumonia distress (ARDS). While we confirm lymphopenia associated...
Q fever is a zoonosis caused by Coxiella burnetii. Acute infection mainly asymptomatic. In other cases it causes flu-like illness, pneumonia, or an hepatitis. We present atypical case of acute revealed massive pleural effusion.
Background: Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19.Methods: FORCE was a double-blind, placebo-controlled study. Patients receiving oxygen support ≥5 L/min to maintain SpO2 > 93% (WHO scale ≥ 5) were randomly assigned, 1:1 ratio placebo arms. Avdoralimab (500 mg loading dose followed by 200 maintenance dose) or (normal saline) administered intravenously every 48 h until...